<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053165</url>
  </required_header>
  <id_info>
    <org_study_id>LB-001</org_study_id>
    <nct_id>NCT05053165</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LISCure Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LISCure Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the safety and tolerability of multiple ascending doses of&#xD;
      LB-P6 or LB-P8 in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is randomised, double-blind, placebo-controlled, single centre study to assess the&#xD;
      safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy&#xD;
      participants.&#xD;
&#xD;
      A total of up to 30 healthy participants will be enrolled in 2 cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 12, 2021</start_date>
  <completion_date type="Anticipated">January 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants through adverse events as assessed by NCI-CTCAE v5.0</measure>
    <time_frame>Measurements at Baseline till 14 days after the last dose of study drug</time_frame>
    <description>Number of participants with treatment related adverse events as assessed by NCI-CTCAE v5.0</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>A (LB-P6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (LB-P8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered once daily orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be administered once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB-P6</intervention_name>
    <description>Healthy subjects will be randomized to receive LB-P6 once daily orally</description>
    <arm_group_label>A (LB-P6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB-P8</intervention_name>
    <description>Healthy subjects will be randomized to receive LB-P8 once daily orally</description>
    <arm_group_label>B (LB-P8)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Healthy subjects will be randomized to receive placebo once daily orally</description>
    <arm_group_label>C (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18 to 65 years (inclusive at the time of consent).&#xD;
&#xD;
          2. BMI ≥ 18 to ≤ 32 kg/m2 and with weight ≥ 50 kg at Screening.&#xD;
&#xD;
          3. Must have a negative urine drug screen at the Screening Visit and the day before&#xD;
             dosing (Day -1); one repeat urine drug may be conducted for a suspected false positive&#xD;
             result.&#xD;
&#xD;
          4. Female participants should meet 1 of the following criteria before they can&#xD;
             participate in the study:&#xD;
&#xD;
               1. Not of childbearing potential, defined as surgically sterile for at least 12&#xD;
                  months prior to screening or postmenopausal&#xD;
&#xD;
               2. Of childbearing potential and agrees to take effective contraceptive measures&#xD;
                  throughout the study period from study entry (ie, screening) until at least 3&#xD;
                  months after the last dose of IP.&#xD;
&#xD;
               3. Of childbearing potential and in an exclusive relationship with a partner who has&#xD;
                  had a bilateral vasectomy at least 6 months prior to study entry.&#xD;
&#xD;
             Female participant of childbearing potential must have a negative serum pregnancy test&#xD;
             at Screening, and a negative urine pregnancy test at Baseline (ie, Day -1), and be&#xD;
             willing to have additional pregnancy tests, as required, throughout the study, at the&#xD;
             discretion of the PI or designee.&#xD;
&#xD;
          5. Male participant: has undergone bilateral vasectomy (at least 6 months prior to study&#xD;
             entry) or agrees to use effective contraceptive measures and not donate sperm&#xD;
             throughout the study period from study entry (ie, Screening) until at least 3 months&#xD;
             after the last dose of IP.&#xD;
&#xD;
          6. Must agree to adhere to the current state and national advice regarding minimising&#xD;
             exposure to COVID-19 from the first Screening Visit until the EOS Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female participants who are pregnant, lactating, or who plan to become pregnant within&#xD;
             90 days of the EOS Visit.&#xD;
&#xD;
          2. The participant has either a history or presence of any clinically significant&#xD;
             immunological disorder/disease (such as autoimmune diseases, etc.), cardiovascular,&#xD;
             thromboembolic events, respiratory, metabolic, renal, hepatic, gastrointestinal,&#xD;
             endocrinological (particularly diabetes or prediabetes), haematological,&#xD;
             dermatological, venereal, neurological, chronic infectious or psychiatric disease or&#xD;
             other major disorder that, in the opinion of the PI or designee, may interfere with&#xD;
             trial compliance, completion, or accurate assessment of trial outcomes or safety.&#xD;
&#xD;
          3. The participant has taken prescription (including antibiotics and anti-virals) or non&#xD;
             prescription medication, herbal remedies, vitamins or minerals, any probiotics and&#xD;
             yeast supplements within 14 days prior to the first dose of IP unless in the opinion&#xD;
             of the PI or designee the medication will not compromise participant safety or&#xD;
             interfere with study procedures or data validity. Participants may be rescreened after&#xD;
             a washout period of 14 days. Use of contraceptives and paracetamol up to 2 g/day&#xD;
             and/or nonsteroidal anti inflammatory drugs (NSAIDs) for symptomatic relief of minor&#xD;
             symptoms are allowed.&#xD;
&#xD;
          4. The participant has a substance abuse-related disorder or has a history of drug,&#xD;
             alcohol, and/or substance abuse deemed significant by the PI or designee. Any&#xD;
             participant with a positive screen for drugs of abuse or alcohol at Screening or on&#xD;
             Day -1 will also be excluded.&#xD;
&#xD;
          5. The participant has taken any IPs within 30 days prior to the first dose of IP or 5&#xD;
             half-lives, whichever is longer.&#xD;
&#xD;
          6. Positive test result for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HbsAg), or hepatitis C virus antibody (anti-HCV), FOB at Screening.&#xD;
&#xD;
          7. The participant has a fever (body temperature &gt; 38°C) or symptomatic viral or&#xD;
             bacterial infection within 2 weeks prior to admission to the clinical research unit&#xD;
             (CRU).&#xD;
&#xD;
          8. The participant has undergone vaccination (including with a live-attenuated vaccine)&#xD;
             within 30 days prior to Baseline (Day -1) through to the end of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire Kim</last_name>
    <phone>31-706-1718</phone>
    <phone_ext>+82</phone_ext>
    <email>hjkim@liscure.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cmax Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Kate Beard</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Newchurch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

